

Hemolytic uremic syndrome induced by infusion of oxaliplatin: a case report

Patrizia Racca¹, Rosella Spadi¹, Gianluca Fora¹, Laura Fanchini¹,
Giuliana Ritorto², Laura Ferrari¹, Francesco Pinta¹, Patrizia Lista²,
and Libero Ciuffreda²

¹SSCVD Colorectal Cancer Unit, and ²SC Medical Oncology 1, AOU San Giovanni Battista, Turin, Italy.

ABSTRACT

Introduction. Oxaliplatin is a third-generation platinum compound with proven antitumor activity in the treatment of colorectal cancer. The occurrence of life-threatening hemolytic uremic syndrome has been observed after oxaliplatin therapy. The kind of tumor and treatment modalities seem to influence the onset of hemolytic uremic syndrome.

Methods. The clinical course of the case is reviewed and compared with reports of other similar cases in the literature.

Results. We describe the development of hemolytic uremic syndrome as a result of prolonged oxaliplatin treatment of a colon cancer patient.

Conclusions. Although this rare event requires the concurrence of other unknown factors, it should be considered in a decision-making setting.

Key words: chemotherapy, colorectal cancer, hemolytic uremic syndrome, oxaliplatin.

Author's conflicts of interest: none.

Correspondence to: Dr.ssa Patrizia Racca, MD, Chief, SSCVD Colorectal Cancer Unit, Medical Oncology 1, AOU S. Giovanni Battista, Cso Bramante 88, 10126 Turin, Italy.
Tel 0039-011-633-5504;
fax 0039-011-633-4476;
e-mail pracca@molinette.piemonte.it

Received October 4, 2010;
accepted December 10, 2010.